The initiative, spearheaded by Dr. Rebecca Ahrens-Nicklas and Dr. Lindsey A. George, targets four specific categories of rare liver-related genetic diseases: urea cycle disorders, organic acidemias, severe protein C deficiency, and hemophilia A. By building on the success of the hospital's previous clinical breakthroughs, the team aims to replace lifelong infusion regimens and high-risk liver transplants with precise, one-time gene corrections.

The project utilizes a three-pronged approach to bridge the gap between laboratory innovation and clinical reality. Researchers will refine lipid nanoparticle systems for base and prime editing, conduct formal clinical trials to establish safety and efficacy, and develop a regulatory framework to expand access through community-based treatment hubs. By shifting from bespoke interventions to a scalable model, the hospital seeks to address the critical mortality risks that currently leave many infants without viable options before their condition progresses.